MedTrace Logo

A Study of HGS1029 (AEG40826-2HCl) in Subjects With Advanced Solid Tumors

NCT00708006 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2013-11-07

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and tolerability of HGS1029 in subjects with advanced solid tumors and to determine a phase 2 dose.

Conditions

Interventions

DRUG

HGS1029

Escalating doses by IV (in the vein), on days 1, 8 and 15 of each 28-day cycle. Number of cycles: until disease progression or unacceptable toxicity

Sponsors & Collaborators

  • Human Genome Sciences Inc.

    lead INDUSTRY

Principal Investigators

  • Gilles Gallant, B. Pharm.,Ph.D. · Human Genome Sciences Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2011-12-31
Completion
2012-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00708006 on ClinicalTrials.gov